根据国药控股股份有限公司公告，截至2025年9月30日止九个月，公司旗下中国医疗器械有限公司实现营业收入54,693,011,286.36元，同比下降2.41%。同期，归属于母公司所有者的综合收益总额为395,277,818.67元，同比下降2.71%。公司同期实现营业利润962,113,681.56元，同比下降10.34%。经营活动产生的现金流量净额为-4,128,048,873.08元，较上年同期-8,182,735,498.07元下降49.55%。
截至报告期末，公司总资产达到64,134,169,584.46元，较期初增长4.01%；归属于母公司所有者权益合计为8,188,821,084.04元，较期初增长3.86%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.